Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MOMENTA PHARMACEUTICALS INCMNTA · Entity 146313 | Chief Operating Officer | February 07, 2017 | February 09, 2017 |
| Voyager Therapeutics, Inc.VYGR · Entity 6271 | Chief Operating Officer | January 21, 2020 | January 29, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MOMENTA PHARMACEUTICALS INC
Report date February 07, 2017 · Filed February 09, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.85 · Expires 2027-02-07 | Direct | 48,000 |
Reported balance
After 2017-02-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-02-07 · Grant · Acquired 48,000 · Balance 48,000 F1: Subject to certain criteria, the stock option will vest and become exercisable with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 24,000 |
Reported balance
After 2017-02-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-02-07 · Grant · Acquired 24,000 · Balance 24,000 F2: Each restricted stock unit represents a contingent right to receive one share of MNTA common stock. F3: Subject to certain criteria, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to certain criteria, the stock option will vest and become exercisable with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years.
F2: Each restricted stock unit represents a contingent right to receive one share of MNTA common stock.
F3: Subject to certain criteria, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years.
Voyager Therapeutics, Inc.
Report date January 21, 2020 · Filed January 29, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,276 |
Reported balance
After 2020-01-21 transaction · row 1
1 source rowRow 1 · 2020-01-21 · Sale · Disposed 3,724 · Balance 26,276 F1: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 11, 2020. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.15 to $13.77, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 11, 2020. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.15 to $13.77, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 21, 2020 Filed Jan 29, 2020 22:26 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 3,724 | $13.36 | $49,752.64 |
DisclosureSEC source: 0001104659-20-008188 · a4.xml · nonDerivative · entry 1 Ottmer Matthew P. · CIK 0001659870 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,276 F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 11, 2020. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.15 to $13.77, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| January 11, 2019 Filed Jan 18, 2019 01:44 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $9.10 | $0.00 |
DisclosureSEC source: 0001104659-19-002347 · a4.xml · derivative · entry 2 Ottmer Matthew P. · CIK 0001659870 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-01-11 F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, January 11, 2019. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| January 11, 2019 Filed Jan 18, 2019 01:44 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-002347 · a4.xml · nonDerivative · entry 1 Ottmer Matthew P. · CIK 0001659870 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · shares: Consists of shares of common stock issuable under an aggregate of 30,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, January 11, 2019. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| March 07, 2018 Filed Mar 10, 2018 00:12 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $28.72 | $0.00 |
DisclosureSEC source: 0001104659-18-016416 · a4.xml · derivative · entry 1 Ottmer Matthew P. · CIK 0001659870 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2028-03-07 F1 · derivative.exercise_date: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of the Vesting Commencement Date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| September 14, 2017 Filed Sep 18, 2017 20:13 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $15.87 | $0.00 |
DisclosureSEC source: 0001104659-17-057639 · a4.xml · derivative · entry 1 Ottmer Matthew P. · CIK 0001659870 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2027-09-14 F1 · derivative.exercise_date: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The vesting commencement date (the "Vesting Commencement Date") of the option is September 11, 2017. The option vests over four years, with 25% of the shares of common stock underlying the option vesting upon the one-year anniversary of the Vesting Commencement Date and the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 16:52 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantRestricted Stock Units · Derivative | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002062 · edgar.xml · derivative · entry 2 Ottmer Matthew P. · CIK 0001659870 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNTA common stock. F3 · derivative.exercise_date: Subject to certain criteria, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. F3 · derivative.expiration_date: Subject to certain criteria, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 16:52 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantStock Option (Right to Buy) · Derivative | 48,000 | $0.00 Strike: $18.85 | $0.00 |
DisclosureSEC source: 0001179110-17-002062 · edgar.xml · derivative · entry 1 Ottmer Matthew P. · CIK 0001659870 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2027-02-07 F1 · derivative.exercise_date: Subject to certain criteria, the stock option will vest and become exercisable with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.